Business
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Lance Alstodt, BioRestorative’s CEO, and Francisco Silva, the Company’s Vice President of Research and Development, will be p
About this update from Biorestorative Therapies, Inc.
[{"type":"image","alt":"BioRestorative Therapies, Inc","displaySize":"","headline":null,"caption":"BioRestorative Therapies, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBsy.n130Az83pQRRSvCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992","width":300,"height":122}},"lazy":false},{"type":"text","content":"MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC.","length":379,"tagName":"p"},{"type":"text","content":"Lance Alstodt, BioRestorative’s CEO, and Francisco Silva, the Company’s Vice President of Research and Development, will be participating in a panel titled “Stem Cell Therapy – A Space That is Ready to have its Day,” to be moderated by Jason McCarthy, Ph.D., Maxim Group’s Senior Managing Director, Head of Biotechnology Research.","length":330,"tagName":"p"},{"type":"text","content":"BioRestorative management will also be meeting with institutional investors in a one-on-one format during the event. Due to the format of the event, no webcast will be available.","length":178,"tagName":"p"},{"type":"text","content":"About BioRestorative Therapies, Inc.","length":36,"tagName":"p"},{"type":"text","content":"BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:","length":334,"tagName":"p"},{"type":"text","content":"• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of...